Dubious past credentials for the team?, page-8

I am looking to make a small investment in medical marijuana stocks. I have come across an article that mentions ZNO while researching medical marijuana stocks. I would like Paul at sometime in the future to secure a contract in NZ, Australia and especially Canada with one of their largest marijuana medical companies.

https://thegreenfund.com/will-this-asx-cannabis-stock-soar-amid-the-coronavirus Click on Link, to read full version

Pot stocks have been experiencing a downturn for the latter half of 2019 and this has continued into 2020. Given that pot stocks don't exist in a vacuum, you can be pretty certain that the ongoing corona crisis isn't going to do any favours for the already struggling global cannabis market.By that same token, in order to best wade through the current uncertainty regarding COVID-19 and how it relates to pot stocks, it helps to look toward the broader global market to see which stocks are weathering the current storm. One such stock is ASX-listed Zoono, (ASX:ZNO), which produces antimicrobial products.

Zoono shares skyrocketed after the company stated that its Z71 Microbe Shield surface sanitizer was highly effective against the bovine Coronavirus achieving 99.99% efficacy in just five minutes.

With many believing that Zoono's technology will be effective against the Coronavirus, investors flocked to the company. Great, but what's the connection to pot stocks?

Botanix Pharmaceutical's Antimicrobial Asset

When looking at a phenomenon like Coronavirus, we're reminded of the growing frequency of bacterial diseases and how they're becoming increasingly immune to current treatments.Due to the overuse of medication, bacteria have developed significant resistance to current antibiotic treatments. On top of this, antibiotics are said to remove more drug-sensitive forms of bacteria, leaving the more resilient forms to propagate.

This overuse of medication is occurring primarily because in many cases, they are being incorrectly prescribed. Studies show that antibiotic therapy is incorrect in 30% to 50% of cases. This alone can cause unnecessary antibacterial resistance and many fear this is precisely what will occur with regards to COVID-19.

This is why we think Botanix Pharma (ASX:BOT) is a wise investment given the early evidence surrounding their antimicrobial product BTX 1801.

Similarly to Zoono, studies revealed that Botanix's drug, BTX 1801, was capable of tackling a range of different bacteria, among both humans and animals. Additionally, the synthetic CBD in Botanix's product kills bacteria within three hours and was shown to lessen the bacteria's ability to develop resistance to the antibiotics.

The cannabis-derived drug has so far proved effective against two superbugs, staphylococcus (staph infections) and methicillin-resistant staph Aureus (MRSA).